FindTrial
Sign In

A clinical trial to study the anti-inflammatory effect of Virecanakarma in Ki?ibhaku??ha (Psoriasis)

A Clinico-Comparative study on the effect of Virecanakarma with Kalya¯n?aka gud?a and Ma¯n?ibhadra gud?a on Inflammatory markers in Ki?ibhaku??ha (Psoriasis) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/054849
Enrollment
40
Registered
2023-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

None listed

Sponsors

S.V. Ayurvedic college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age group 18-65 years. Patients presenting with the signs and symptoms of Kit?ibha. Patients presenting with the signs and symptoms of Psoriasis. Patients who are eligible for Virecana.

Exclusion criteria

Exclusion criteria: Patients below the age of 18 and above the age of 65 years. Patients with Diabetes and Hypertension. Patients with TB, HIV, Cancer and other major systemic diseases. Patients who are not eligible for Virecana.

Design outcomes

Primary

MeasureTime frame
To prove the Anti-inflammatory effect of Virecanakarma by comparing the efficacies of Kalya¯n?aka gud?a & Ma¯n?ibhadra gud?a by evaluation of Inflammatory markers Timepoint: At baseline, aftr completion of treatment (11th-18th day), 7weeks—

Secondary

MeasureTime frame
To prove the Anti-inflammatory effect of Virecanakarma by comparing the efficacies of Kalya¯n?aka gud?a & Ma¯n?ibhadra gud?a by evaluation of Inflammatory markersTimepoint: At baseline, after completion of treatment( 11th-18th day), aftr 7weeks—

Countries

India

Contacts

Public ContactGadam Nageshkumar Govinda

S.V. Ayurvedic College and Hospital

dr.lpvedantam@gmail.com9440218860

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026